Trial intelligence / Profile preview

Phase Ib/II study of HDM2017 plus fruquintinib in advanced colorectal cancer

CTR20262213Phase 2Active

Sponsor

杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)

Start

Jul 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1